372 related articles for article (PubMed ID: 21193039)
21. Cinnamates and cinnamamides inhibit fungal 17beta-hydroxysteroid dehydrogenase.
Kristan K; Starcević S; Brunskole M; Rizner TL; Gobec S
Mol Cell Endocrinol; 2006 Mar; 248(1-2):239-41. PubMed ID: 16337334
[TBL] [Abstract][Full Text] [Related]
22. Phytoestrogens inhibit human 17beta-hydroxysteroid dehydrogenase type 5.
Krazeisen A; Breitling R; Möller G; Adamski J
Mol Cell Endocrinol; 2001 Jan; 171(1-2):151-62. PubMed ID: 11165023
[TBL] [Abstract][Full Text] [Related]
23. Synthesis and biological evaluation of 17beta-hydroxysteroid dehydrogenase type 1 (17beta-HSD1) inhibitors based on a thieno[2,3-d]pyrimidin-4(3H)-one core.
Lilienkampf A; Karkola S; Alho-Richmond S; Koskimies P; Johansson N; Huhtinen K; Vihko K; Wähälä K
J Med Chem; 2009 Nov; 52(21):6660-71. PubMed ID: 19824648
[TBL] [Abstract][Full Text] [Related]
24. Complementary deoxyribonucleic acid cloning and enzymatic characterization of a novel 17beta/3alpha-hydroxysteroid/retinoid short chain dehydrogenase/reductase.
Su J; Lin M; Napoli JL
Endocrinology; 1999 Nov; 140(11):5275-84. PubMed ID: 10537158
[TBL] [Abstract][Full Text] [Related]
25. Integrated view on 17beta-hydroxysteroid dehydrogenases.
Moeller G; Adamski J
Mol Cell Endocrinol; 2009 Mar; 301(1-2):7-19. PubMed ID: 19027824
[TBL] [Abstract][Full Text] [Related]
26. Steroid metabolism in breast cancer.
Foster PA
Minerva Endocrinol; 2008 Mar; 33(1):27-37. PubMed ID: 18277377
[TBL] [Abstract][Full Text] [Related]
27. Perspectives in understanding the role of human 17beta-hydroxysteroid dehydrogenases in health and disease.
Meier M; Möller G; Adamski J
Ann N Y Acad Sci; 2009 Feb; 1155():15-24. PubMed ID: 19250188
[TBL] [Abstract][Full Text] [Related]
28. Enzymes as modulators in malignant transformation.
Vihko P; Herrala A; Härkönen P; Isomaa V; Kaija H; Kurkela R; Li Y; Patrikainen L; Pulkka A; Soronen P; Törn S
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):277-83. PubMed ID: 15860271
[TBL] [Abstract][Full Text] [Related]
29. Expression of 17beta-hydroxysteroid dehydrogenases and other estrogen-metabolizing enzymes in different cancer cell lines.
Smuc T; Rizner TL
Chem Biol Interact; 2009 Mar; 178(1-3):228-33. PubMed ID: 19022235
[TBL] [Abstract][Full Text] [Related]
30. STX2171, a 17β-hydroxysteroid dehydrogenase type 3 inhibitor, is efficacious in vivo in a novel hormone-dependent prostate cancer model.
Day JM; Foster PA; Tutill HJ; Schmidlin F; Sharland CM; Hargrave JD; Vicker N; Potter BV; Reed MJ; Purohit A
Endocr Relat Cancer; 2013 Feb; 20(1):53-64. PubMed ID: 23132791
[TBL] [Abstract][Full Text] [Related]
31. A challenge for medicinal chemistry by the 17β-hydroxysteroid dehydrogenase superfamily: an integrated biological function and inhibition study.
Lin SX; Poirier D; Adamski J
Curr Top Med Chem; 2013; 13(10):1164-71. PubMed ID: 23647539
[TBL] [Abstract][Full Text] [Related]
32. Identification of chemically diverse, novel inhibitors of 17β-hydroxysteroid dehydrogenase type 3 and 5 by pharmacophore-based virtual screening.
Schuster D; Kowalik D; Kirchmair J; Laggner C; Markt P; Aebischer-Gumy C; Ströhle F; Möller G; Wolber G; Wilckens T; Langer T; Odermatt A; Adamski J
J Steroid Biochem Mol Biol; 2011 May; 125(1-2):148-61. PubMed ID: 21300150
[TBL] [Abstract][Full Text] [Related]
33. Inhibitory effects of fluorine-substituted estrogens on the activity of 17beta-hydroxysteroid dehydrogenases.
Deluca D; Möller G; Rosinus A; Elger W; Hillisch A; Adamski J
Mol Cell Endocrinol; 2006 Mar; 248(1-2):218-24. PubMed ID: 16406285
[TBL] [Abstract][Full Text] [Related]
34. Subcellular localization and membrane topology of 17β-hydroxysteroid dehydrogenases.
Tsachaki M; Odermatt A
Mol Cell Endocrinol; 2019 Jun; 489():98-106. PubMed ID: 30864548
[TBL] [Abstract][Full Text] [Related]
35. Recent insight on the control of enzymes involved in estrogen formation and transformation in human breast cancer.
Pasqualini JR; Chetrite GS
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):221-36. PubMed ID: 15860265
[TBL] [Abstract][Full Text] [Related]
36. Relative involvement of three 17beta-hydroxysteroid dehydrogenases (types 1, 7 and 12) in the formation of estradiol in various breast cancer cell lines using selective inhibitors.
Laplante Y; Rancourt C; Poirier D
Mol Cell Endocrinol; 2009 Mar; 301(1-2):146-53. PubMed ID: 18812208
[TBL] [Abstract][Full Text] [Related]
37. Inhibitors of type II 17beta-hydroxysteroid dehydrogenase.
Poirier D; Bydal P; Tremblay MR; Sam KM; Luu-The V
Mol Cell Endocrinol; 2001 Jan; 171(1-2):119-28. PubMed ID: 11165020
[TBL] [Abstract][Full Text] [Related]
38. Inhibition of type 1 17β-hydroxysteroid dehydrogenase impairs the synthesis of 17β-estradiol in endometriosis lesions.
Delvoux B; D'Hooghe T; Kyama C; Koskimies P; Hermans RJ; Dunselman GA; Romano A
J Clin Endocrinol Metab; 2014 Jan; 99(1):276-84. PubMed ID: 24187399
[TBL] [Abstract][Full Text] [Related]
39. Zebrafish 17beta-hydroxysteroid dehydrogenases: an evolutionary perspective.
Mindnich R; Adamski J
Mol Cell Endocrinol; 2009 Mar; 301(1-2):20-6. PubMed ID: 19111899
[TBL] [Abstract][Full Text] [Related]
40. Analysis and characteristics of multiple types of human 17beta-hydroxysteroid dehydrogenase.
Luu-The V
J Steroid Biochem Mol Biol; 2001; 76(1-5):143-51. PubMed ID: 11384872
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
